Copyright © Inderes 2011 - present. All rights reserved.

Herantis Pharma

1.65

 

EUR

 

-0.6 %

Corporate customer

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

4,214 following
Compare
-0.6%
+30.95%
+10.37%
-0.3%
+4.76%
+3.77%
-25.22%
-78.18%
-83.62%

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Read more
Market cap
33.27M EUR
Turnover
25.06K EUR
P/E (adj.) (24e)
-6.33
EV/EBIT (adj.) (24e)
-6.34
P/B (24e)
158.41
EV/S (24e)
3,330.57
Dividend yield-% (24e)
-
Coverage
Recommendation
Accumulate
Target price
2.20 EUR
Updated
2024-08-23
Disclaimer
Latest research

Latest analysis report

Released: 2024-08-23

Latest extensive report

Released: 2024-06-25

Financial calendar
6/3
2025

Annual report '24

24/4
2025

General meeting '24

21/8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Pia intervjuade chefsanalytiker Antti Siltanen och de diskuterade självklart detta företag. We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does...
6/26/2024, 7:40 PM
by börsen84
2
Herantis Pharma är ett finländskt bioteknikföretag som specialiserar sig på läkemedelsforskning och utvecklar behandlingar för flera sjukdomar, såsom Parkinsons sjukdom, skleros och bröstcancer. Företaget har en bred produktportfölj i olika kliniska faser. Herantis Pharma bildades...
6/26/2024, 1:55 PM
by börsen84
2
New series of articles! We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply...
9/10/2024, 6:49 AM
by Jesper Hagman
1
Antti Vuolanto, VD för Herantis Pharma, berättar om bioteknikföretaget som en investeringsmöjlighet. Inderes Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024 -... Time: 2024-12-03 13:50 Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an...
12/3/2024, 1:56 PM
by börsen84
0
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.